TSX:ONC 0.55 CAD -0.03 -5.17% Volume: 132,660 October 5, 2015
NASDAQ:ONCY 0.42 USD -0.02 -4.11% Volume: 280,447 October 5, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

September 25, 2015 Oncolytics Biotech® Inc. Collaborators Present Data from Clinical Study in Multiple Myeloma
September 09, 2015 Media Advisory - Oncolytics Biotech® Inc. to Participate in the Baird 2015 Healthcare Conference
August 27, 2015 Oncolytics Biotech® Inc. Collaborators to Present Survival Data from REO 016 Study in Non-Small Cell Lung Cancer
Sign up to receive e-mail updates *